Buradasınız

Anasayfa » Content

Comparative study of insulin glargine and NPH insulin in poorly controlled type 2 diabetic patients on OHA

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2015

Key Words:

Author Name
Abstract (2. Language): 
Introduction: Diabetes mellitus is one of the most common endocrine disorders. Approximately 180 million individual worldwide have diabetes and by 2030 this number is expected to double. India has largest number of diabetics in the world with a prevalence of 2.4% in rural and 4-11.6% in urban population. Most diabetic patients are initially treated with OHA. Those who are poorly controlled on OHA are shifted to or combined with Insulin therapy to achieve good glycemic control. Aims and objective: To compare the efficacy and the incidence of hypoglycemia with addition of Insulin Glargine vs. NPH insulin in Type 2 Diabetes mellitus patients poorly controlled on OHA. Result and observation: Prior to initiating Insulin therapy mean value of HbA1c in group 1 and group 2 being 11.70+ 1.30 and 11.90 + 1.64 respectively. Number of patients achieving good glycemic control in treatment group 1 was 8 (40%) of the 20 patients while only 6 patients (30%) achieved that level in NPH insulin group. The hypoglycemic events reported were higher in NPH insulin group as compared to Glargine Group. In Glargine Group Overall 12 patients reported to have hypoglycemic events (13 events) while 15 patients taking NPH insulin reported hypoglycaemic events (26 events).
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-comparative-study-insulin-glargine-and-nph-insulin-poorly-controlled-type-2-diabetic-patients-oha.pdf
  • 2
233
241
  • English

REFERENCES

References: 

1 . World Health Organization. Fact sheet: diabetes. No.312,
http://www.who.int/mediacentre/factsheets/en/index.html.
2 . Epidemiology of chronic non communicable disease and conditions, in Park K : Park’s Textbook of preventive
and social medicine. India M/S Banarsidas Bhanot, 18th
3 . Sherwin RS. Diabetes mellitus, in Goldman L, Bennett JC (eds): Cecil EWtbook of Medicine. Philadelphia, WB
Saunders, 2000, 1263-85
4 . Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 11: Reduction in HbA]C with basal
insulin supplement, sulfonylurea, bi guanide therapy in maturity-onset diabetes: a multi-center study. Diabetes.l985;
34:793-8.
5 . Nathan DM, Initial management of glycemia in Type.2 Diabetes mellitus. N Engl J Med.2002; 147: 1342-9
6 . American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care. 2003;26(suppll):Sl-
SlS6.
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 233-241
235
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
7 . Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study Group: Glycemic control with diet,
sulfonylurea, metformin, or insulin. JAMA. 1999; 281:2005- 12
8 . Stratton 1M, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-11
9 . Lepore M, Pampanelli S, Fanelli C, et al. Pharrnacokinetics and pharmacodynamics of subcutaneous injection of
long acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous
subcutaneous infusion of insulin lispro; Diabetes. 2000; 49:2142-8.
10 . Riddle MC, Rosenstock J, Gerich J. The treat to target trial: randomized addition of glargine or human NPH
insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-6.
11 .American Diabetes association. Standards of Medical care 2013. Final 21 Dec 2012 (1) ppt
12 . Yki-Jarvinen H, Ryysy L, Nikkila K, Tuiokas T, Vanamo R, Heikkiia Comparison of bedtime insulin regimens
in patients with type 2.diabetes mellitus . A randomized mntrolled trial. Ann Intern Med. l999;130:389.96
13 . Yki-Jarvinen H, Dressler A, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with
bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2
diabetes. Diabetes Care. 2000;23 : 1130-6
14 . Fritsche A, Schweizer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral
protamine hagedom insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized controlled
trial. Ann Intern Med.2003;138:952-9
15 . Rosenstock J, Schwartz is; CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin filtr'aapy in type 2
diabetes: 28 week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care.2001;24:631-6
16 .Christopher JD, Greg LP, Gillman MK, Kate M. Insulin glargine: An updated review of its use in the
management of diabetes mellitus. Drugs. 2003;63: 1743-78.
17 . Riddle MC, Rosenstock J. Treatment to target study: Insulin glargine vs NPH insulin added therapy of type 2
diabetes. Diabetes. 2005;51(Suppl2)

Thank you for copying data from http://www.arastirmax.com